Pharminent · Daily Brief
November 11, 2026
Regulatory & Approvals
FDA approves Bayer’s Sunharbo for secondary stroke prevention
The FDA approved Bayer’s asundexian, branded Sunharbo, a once-daily pill, for secondary stroke prevention in adults. The source reports it is the first FDA-approved drug in a new class of cardiovascular medicines.
MedCity News →$BAYRY
FDA approves Merck’s Pimjetmi for tenosynovial giant cell tumor
Merck’s Pimjetmi was cleared in the US for tenosynovial giant cell tumor, making it the third FDA-approved treatment for the rare disorder.
Pharmaphorum →$MRK
Clinical Data
Beam’s base editing sickle cell therapy meets pivotal trial goal
Beam’s base editing therapy risto-cel met its goal in a pivotal trial in sickle cell disease. The company could submit an FDA application as soon as the end of the year.
BioPharma Dive →
PepGen shares jump on early myotonic dystrophy data
PepGen reported early results from a small study of its therapy for myotonic dystrophy type 1, and its shares rose on the findings.
BioPharma Dive →
Levicept presents new LEVI-04 osteoarthritis data at ACR
Levicept reported new data on LEVI-04 in patients with osteoarthritis at ACR, which the company says support its potential to become the first new systemic treatment for the condition in more than two decades.
Pharmaphorum →
Deals & Partnerships
AstraZeneca acquires vaccine developer Omniose
AstraZeneca has acquired Omniose, a US biotech developing polysaccharide conjugate vaccines for bacterial infections, following a three-year partnership between the two companies.
Pharmaphorum →$AZN
ProBio licenses early-stage antibody from AbTis worldwide
ProBio entered an exclusive worldwide licensing agreement with South Korean biotech AbTis to develop and commercialize an early-stage therapeutic antibody asset.
Pharmaceutical Technology →
Children’s Tumor Foundation takes equity stake in GondolaBio program
The Children’s Tumor Foundation is providing clinical expertise and scientific infrastructure, rather than cash, in exchange for an equity stake in GondolaBio’s preclinical NF1 drug program.
PharmaVoice →
Business & Finance
Oyster Therapeutics raises $60M for protein degraders
Oyster Therapeutics closed a $60 million Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.
Pharmaceutical Technology →
Pfizer names Cecile Guegan chief financial officer
Cecile Guegan has become Pfizer’s chief financial officer, the company’s first permanent female CFO.
PharmaVoice →$PFE
Democrats move toward probe of MFN drug pricing deals
Incoming Democratic chairs of key congressional committees have taken a step toward investigating most-favored-nation drug pricing agreements struck between drugmakers and the Trump administration, sending letters to manufacturers.
STAT →
Forwarded this? Get your copy free
Sign up free →
Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.